CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators

Author(s): Krishna A. Gajjar*, Anuradha K. Gajjar.

Journal Name: Current Drug Discovery Technologies

Volume 17 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Human GPR40 receptor, also known as free fatty-acid receptor 1, is a Gprotein- coupled receptor that binds long chain free fatty acids to enhance glucose-dependent insulin secretion. In order to improve the resistance and efficacy, computational tools were applied to a series of 3-aryl-3-ethoxypropanoic acid derivatives. A relationship between the structure and biological activity of these compounds, was derived using a three-dimensional quantitative structure-activity relationship (3D-QSAR) study using CoMFA, CoMSIA and two-dimensional QSAR study using HQSAR methods.

Methods: Building the 3D-QSAR models, CoMFA, CoMSIA and HQSAR were performed using Sybyl-X software. The ratio of training to test set was kept 70:30. For the generation of 3D-QSAR model three different alignments were used namely, distill, pharmacophore and docking based alignments. Molecular docking studies were carried out on designed molecules using the same software.

Results: Among all the three methods used, Distill alignment was found to be reliable and predictive with good statistical results. The results obtained from CoMFA analysis q2, r2cv and r2 pred were 0.693, 0.69 and 0.992 respectively and in CoMSIA analysis q2, r2cv and r2pred were 0.668, 0.648 and 0.990. Contour maps of CoMFA (lipophilic and electrostatic), CoMSIA (lipophilic, electrostatic, hydrophobic, and donor) and HQSAR (positive & negative contribution) provided significant insights i.e. favoured and disfavoured regions or positive & negative contributing fragments with R1 and R2 substitutions, which gave hints for the modifications required to design new molecules with improved biological activity.

Conclusion: 3D-QSAR techniques were applied for the first time on the series 3-aryl-3- ethoxypropanoic acids. All the models (CoMFA, CoMSIA and HQSAR) were found to be satisfactory according to the statistical parameters. Therefore such a methodology, whereby maximum structural information (from ligand and biological target) is explored, gives maximum insights into the plausible protein-ligand interactions and is more likely to provide potential lead candidates has been exemplified from this study.

Keywords: GPR40, 3D-QSAR, CoMFA, CoMSIA, HQSAR, type 2 diabetes mellitus, molecular docking, alignments, Sybyl- X, contour maps.

[1]
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J 2014; 7(1): 45-8.
[http://dx.doi.org/10.4066/AMJ.2014.1979] [PMID: 24567766]
[2]
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 2015; 17(7): 675-81.
[http://dx.doi.org/10.1111/dom.12467] [PMID: 25787200]
[3]
Oh DY, Olefsky JM. G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat Rev Drug Discov 2016; 15(3): 161-72.
[http://dx.doi.org/10.1038/nrd.2015.4] [PMID: 26822831]
[4]
Srivastava A, Yano J, Hirozane Y, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 2014; 513(7516): 124-7.
[http://dx.doi.org/10.1038/nature13494] [PMID: 25043059]
[5]
Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett 2014; 24(14): 2991-3000.
[http://dx.doi.org/10.1016/j.bmcl.2014.05.019] [PMID: 24881568]
[6]
Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian J Endocrinol Metab 2016; 20(2): 254-67.
[http://dx.doi.org/10.4103/2230-8210.176351] [PMID: 27042424]
[7]
Christiansen E, Urban C, Merten N, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 2008; 51(22): 7061-4.
[http://dx.doi.org/10.1021/jm8010178] [PMID: 18947221]
[8]
Lin DC-H, Zhang J, Zhuang R, et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 2011; 6(11)e27270
[http://dx.doi.org/10.1371/journal.pone.0027270] [PMID: 22087278]
[9]
Lu H, Fei H, Yang F, et al. Discovery of novel orally bioavailable GPR40 agonists. Bioorg Med Chem Lett 2013; 23(10): 2920-4.
[http://dx.doi.org/10.1016/j.bmcl.2013.03.060] [PMID: 23582779]
[10]
Mikami S, Kitamura S, Negoro N, et al. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes. J Med Chem 2012; 55(8): 3756-76.
[http://dx.doi.org/10.1021/jm2016123] [PMID: 22428944]
[11]
Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14(3): 271-8.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01525.x] [PMID: 22051148]
[12]
Houze JB, Zhu L, Sun Y, et al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett 2012; 22(2): 1267-70.
[http://dx.doi.org/10.1016/j.bmcl.2011.10.118] [PMID: 22217876]
[13]
Li Z, Qiu Q, Geng X, Yang J, Huang W, Qian H. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs 2016; 25(8): 871-90.
[http://dx.doi.org/10.1080/13543784.2016.1189530] [PMID: 27171154]
[14]
Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, Chang CJ. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity. Am J Physiol Endocrinol Metab 2013; 304(6): E668-76.
[http://dx.doi.org/10.1152/ajpendo.00419.2012] [PMID: 23341496]
[15]
Li Z, Wang X, Xu X, et al. Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. Bioorg Med Chem 2015; 23(20): 6666-72.
[http://dx.doi.org/10.1016/j.bmc.2015.09.010] [PMID: 26420383]
[16]
Takano R, Yoshida M, Inoue M, et al. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558. Bioorg Med Chem 2015; 23(17): 5546-65.
[http://dx.doi.org/10.1016/j.bmc.2015.07.028] [PMID: 26234904]
[17]
Nilewar S, Kathiravan M. 3D CoMFA, CoMSIA, topomer CoMFA and HQSAR studies on aromatic acid esters for carbonic anhydrase inhibitory activity. J Chemometr 2014; 28(1): 60-70.
[http://dx.doi.org/10.1002/cem.2574]
[18]
Caballero J. 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds. J Mol Graph Model 2010; 29(3): 363-71.
[http://dx.doi.org/10.1016/j.jmgm.2010.08.005] [PMID: 20863730]
[19]
SYBYL-X Molecular Modeling Software. Tripos Associates, V 12, St Louis, USA 2011 http://www.tripos.com
[20]
Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron 1980; 36(22): 3219-28.
[http://dx.doi.org/10.1016/0040-4020(80)80168-2]
[21]
Cho SJ, Tropsha A. Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J Med Chem 1995; 38(7): 1060-6.
[http://dx.doi.org/10.1021/jm00007a003] [PMID: 7707309]
[22]
Dixit A, Kashaw SK, Gaur S, Saxena AK. Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist. Bioorg Med Chem 2004; 12(13): 3591-8.
[http://dx.doi.org/10.1016/j.bmc.2004.04.016] [PMID: 15186843]
[23]
Jain AN. Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J Comput Aided Mol Des 1996; 10(5): 427-40.
[http://dx.doi.org/10.1007/BF00124474] [PMID: 8951652]
[24]
Cramer R, Bunce J, Patterson D. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Rel 1988; 7: 18-25.
[http://dx.doi.org/10.1002/qsar.19880070105]
[25]
Ståhle L, Wold S. Multivariate data analysis and experimental design in biomedical research. Prog Med Chem 1988; 25: 291-338.
[http://dx.doi.org/10.1016/S0079-6468(08)70281-9] [PMID: 3076969]
[26]
Honório KM, Garratt RC, Andricopulo AD. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators. Bioorg Med Chem Lett 2005; 15(12): 3119-25.
[http://dx.doi.org/10.1016/j.bmcl.2005.04.017] [PMID: 15893927]
[27]
Ugarkar A, Ambre P, Coutinho E, Nandan S, Pissurlenkar R. Extracting structural requirements for activity of GPR119 agonists: A Hologram Quantitative Structure Activity Relationship (HQSAR) study. Can J Chem 2014; 92: 670-6.
[http://dx.doi.org/10.1139/cjc-2014-0129]
[28]
Tong W, Lowis DR, Perkins R, et al. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 1998; 38(4): 669-77.
[http://dx.doi.org/10.1021/ci980008g] [PMID: 9722424]
[29]
Bhansali SG, Kulkarni VM. Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors. SAR QSAR Environ Res 2014; 25(11): 905-37.
[http://dx.doi.org/10.1080/1062936X.2014.969309] [PMID: 25401514]
[30]
Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design--a review. Curr Top Med Chem 2010; 10(1): 95-115.
[http://dx.doi.org/10.2174/156802610790232260] [PMID: 19929826]
[31]
Golbraikh A, Shen M, Xiao Z, Xiao YD, Lee KH, Tropsha A. Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 2003; 17(2-4): 241-53.
[http://dx.doi.org/10.1023/A:1025386326946] [PMID: 13677490]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 1
Year: 2020
Page: [100 - 118]
Pages: 19
DOI: 10.2174/1570163815666180829144431
Price: $65

Article Metrics

PDF: 15
HTML: 1